|520.78||+4.52||+0.88%||Vol 1.61M||1Y Perf -7.92%|
|Jun 7th, 2023 16:00 DELAYED|
|- -||-0.38 -0.07%|
|Target Price||621.93||Analyst Rating||Strong Buy 1.34|
|Potential %||19.42||Finscreener Ranking||★★+ 46.85|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 47.23|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 65.00|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★+ 47.06|
|Price Range Ratio 52W %||33.27||Earnings Rating||Sell|
|Market Cap||200.88B||Earnings Date||27th Jul 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Jul 2023|
|Estimated EPS Next Report||5.43|
|EPS Growth Next 5 Years %||8.50|
|Avg. Weekly Volume||2.08M|
|Avg. Monthly Volume||1.64M|
|Avg. Quarterly Volume||1.37M|
Thermo Fisher Scientific Inc (NYSE: TMO) stock closed at 520.78 per share at the end of the most recent trading day (a 0.88% change compared to the prior day closing price) with a volume of 1.61M shares and market capitalization of 200.88B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 75000 people. Thermo Fisher Scientific Inc CEO is Marc N. Casper.
The one-year performance of Thermo Fisher Scientific Inc stock is -7.92%, while year-to-date (YTD) performance is -5.43%. TMO stock has a five-year performance of 139.97%. Its 52-week range is between 475.77 and 611.06, which gives TMO stock a 52-week price range ratio of 33.27%
Thermo Fisher Scientific Inc currently has a PE ratio of 30.10, a price-to-book (PB) ratio of 4.82, a price-to-sale (PS) ratio of 6.40, a price to cashflow ratio of 26.00, a PEG ratio of 2.32, a ROA of 9.20%, a ROC of 11.23% and a ROE of 18.42%. The company’s profit margin is 16.09%, its EBITDA margin is 26.60%, and its revenue ttm is $33.46 Billion , which makes it $85.33 revenue per share.
Of the last four earnings reports from Thermo Fisher Scientific Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $5.43 for the next earnings report. Thermo Fisher Scientific Inc’s next earnings report date is 27th Jul 2023.
The consensus rating of Wall Street analysts for Thermo Fisher Scientific Inc is Strong Buy (1.34), with a target price of $621.93, which is +19.42% compared to the current price. The earnings rating for Thermo Fisher Scientific Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Thermo Fisher Scientific Inc has a dividend yield of 0.22% with a dividend per share of $1.20 and a payout ratio of 4.00%.
Thermo Fisher Scientific Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 8.38, ATR14 : 11.67, CCI20 : -35.01, Chaikin Money Flow : -0.02, MACD : -7.71, Money Flow Index : 50.60, ROC : -1.25, RSI : 44.29, STOCH (14,3) : 61.65, STOCH RSI : 1.00, UO : 46.67, Williams %R : -38.35), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Thermo Fisher Scientific Inc in the last 12-months were: Debora L. Spar (Sold 200 shares of value $112 278 ), Gianluca Pettiti (Option Excercise at a value of $1 048 133), Gianluca Pettiti (Sold 6 975 shares of value $4 007 999 ), Jim Manzi (Sold 814 shares of value $486 156 ), Jim P. Manzi (Sold 1 814 shares of value $1 070 714 ), Marc N. Casper (Option Excercise at a value of $25 291 213), Marc N. Casper (Sold 265 820 shares of value $148 734 046 ), Michael A. Boxer (Option Excercise at a value of $1 405 473), Michael A. Boxer (Sold 7 283 shares of value $4 302 796 ), Stephen Williamson (Option Excercise at a value of $8 609 328), Stephen Williamson (Sold 54 600 shares of value $32 885 202 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).
CEO: Marc N. Casper
Telephone: +1 781 622-1000
Address: 168 Third Avenue, Waltham 02451, MA, US
Number of employees: 75 000
Thu, 27 Apr 2023 15:15 GMT Thermo Fisher (TMO) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Sat, 15 Apr 2023 01:50 GMT Analysts Top Healthcare Picks: Thermo Fisher (TMO), Moderna (MRNA)- TipRanks. All rights reserved.
Tue, 14 Mar 2023 10:20 GMT Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), VYNE Therapeutics (VYNE)- TipRanks. All rights reserved.
Tue, 07 Feb 2023 02:10 GMT Analysts Offer Insights on Healthcare Companies: The Ensign Group (ENSG), Thermo Fisher (TMO) and Zimmer Biomet Holdings (ZBH)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.